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Background: Polycystic ovary syndrome (PCOS) is a prevalent, complex endocrine disorder characterised by
polycystic ovaries, chronic anovulation and hyperandrogenism leading to symptoms of irregular menstrual cycles,
hirsutism, acne and infertility. Evidence based medical management emphasises a multidisciplinary approach for
PCOS, as conventional pharmaceutical treatment addresses single symptoms, may be contra-indicated, is often
associated with side effects and not effective in some cases. In addition women with PCOS have expressed a strong
desire for alternative treatments. This review examines the reproductive endocrine effects in PCOS for an alternative
treatment, herbal medicine. The aim of this review was to identify consistent evidence from both pre-clinical and
clinical research, to add to the evidence base for herbal medicine in PCOS (and associated oligo/amenorrhoea and
hyperandrogenism) and to inform herbal selection in the provision clinical care for these common conditions.
Methods: We undertook two searches of the scientific literature. The first search sought pre-clinical studies which explained
the reproductive endocrine effects of whole herbal extracts in oligo/amenorrhoea, hyperandrogenism and PCOS. Herbal
medicines from the first search informed key words for the second search. The second search sought clinical studies, which
corroborated laboratory findings. Subjects included women with PCOS, menstrual irregularities and hyperandrogenism.
Results: A total of 33 studies were included in this review. Eighteen pre-clinical studies reported mechanisms of effect and
fifteen clinical studies corroborated pre-clinical findings, including eight randomised controlled trials, and 762 women with
menstrual irregularities, hyperandrogenism and/or PCOS. Interventions included herbal extracts of Vitex agnus-castus,
Cimicifuga racemosa, Tribulus terrestris, Glycyrrhiza spp., Paeonia lactiflora and Cinnamomum cassia. Endocrine outcomes
included reduced luteinising hormone (LH), prolactin, fasting insulin and testosterone. There was evidence for the
regulation of ovulation, improved metabolic hormone profile and improved fertility outcomes in PCOS. There was evidence
for an equivalent effect of two herbal medicines and the pharmaceutical agents bromocriptine (and Vitex agnus-castus) and
clomiphene citrate (and Cimicifuga racemosa). There was less robust evidence for the complementary combination of
spirinolactone and Glycyrrhiza spp. for hyperandrogenism.
Conclusions: Preclinical and clinical studies provide evidence that six herbal medicines may have beneficial effects for
women with oligo/amenorrhea, hyperandrogenism and PCOS. However the quantity of pre-clinical data was limited, and
the quality of clinical evidence was variable. Further pre-clinical studies are needed to explain the effects of herbal
medicines not included in this review with current clinical evidence but an absence of pre-clinical data.* Correspondence: s.arentz@uws.edu.au
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Polycystic ovary syndrome (PCOS) is a complex, common
reproductive and endocrine disorder affecting up to 17.8%
of reproductive aged women [1]. Medical management
places strong emphasis on a multidisciplinary approach as
pharmaceutical treatments appear to be only moderately
effective in treating individual symptoms [2,3]. Conven-
tional pharmaceutical management is limited by the
prevalence of contraindications in women with PCOS [3],
non-effectiveness in some circumstances [4], side effects
[5] and by preferences of women with PCOS for alterna-
tives to pharmaceutical management [6]. This review
examines the mechanisms of effect for a potential alterna-
tive treatment, herbal medicine, and reveals six herbal
medicines with both pre-clinical and clinical data explain-
ing the reproductive endocrinological effects in PCOS and
associated oligo/amenorrhoea and hyperandrogenism.
Complementary medicine (CM) use by women has in-
creased during the past ten years [7-11] with rates of use
ranging between 26% and 91% [8,9]. One of the popular
types of CM is herbal medicine [11,12]. Herbal medi-
cines are known to contain pharmacologically active con-
stituents with physiological effects on female endocrinology
and have been positively associated with reduced inci-
dences of breast cancer, osteoporosis and cardiovascu-
lar disease [13-18].
PCOS is a life-long condition and although the exact
cause is yet to be identified, it is believed to have epigen-
etic origins, influenced by the uterine environment and
behavioural factors [19]. Being overweight exacerbates all
aspects of PCOS due to underlying metabolic disturbances
[3]. Signs and symptoms are mediated by hormonal dis-
order including elevated androgens and fasting insulin,
and abnormal relative ratio of the gonadotropins luteinis-
ing hormone (LH) and follicle stimulating hormone (FSH)
[19]. Endocrine imbalances occur within the framework
of disordered ovarian folliculogenesis, chronic anovula-
tion, clinical signs of hyperandrogenism and metabolic
syndrome [19].
Pharmaceutical treatment for menstrual irregularity
includes the oral contraceptive pill (OCP) and ovulation
induction with clomiphene citrate (clomiphene) [20,21]
depending on fertility needs. Women with PCOS are
however likely to exhibit contraindications for the OCP
[3] and whilst induction of ovulation with clomiphene
has demonstrated success, pregnancy rates remain inex-
plicably low [4]. Up to thirty 30% of women, particularly
overweight women with PCOS, fail to respond to clomi-
phene therapy [4,22,23]. Management for hyperand-
rogenism includes anti-androgens and hypoglycaemic
pharmaceuticals such as metformin [24]. Metfomin has
demonstrated effectiveness for improving insulin sensi-
tivity and hyperandrogenism, however use of metformin
is associated with the high incidence of adverse effectsincluding nausea, vomiting and gastro-intestinal distur-
bances [5].
Herbal medicines are complex interventions with the
potential for synergistic and antagonistic interactions be-
tween compounds [25]. Effects within the body may also
exhibit complexity by simultaneous interactions with
various body systems, both biochemically and by altering
organ function [26]. The focus of this review was studies
investigating whole herbal medicine extracts with direct
effects on reproductive endocrinology for the treatment
of women with irregular menstruation, hyperandrogen-
ism and PCOS. The rationale for using this methodology
was to identify herbal medicines with current scientific
evidence explaining specific reproductive endocrinological
effects in PCOS, oligo/amenorrhoea and hyperandrogen-
ism, to develop understanding for the direct effects of
herbal medicines on reproductive endocrinology and to
highlight herbal medicines for which there was current
scientific evidence supporting herbal medicine selection.
The purpose of this review is to inform clinical decisions
in integrative settings and meet clinicians and consumers
preferences for pragmatic herbal management within an
holistic, individualised treatment frame [27,28].
We compared laboratory evidence including scientific
studies using cell culture and animal models, with clin-
ical data for proof-of-concept effects. A narrative syn-
thesis of pre-clinical studies explaining reproductive
endocrinological effects for herbal medicines with cor-
roborative clinical evidence is presented.
Methods
We used the following definitions. PCOS according to the
Rotterdam diagnostic criteria, specified by the presence of
two out of three features; oligo/amenorrhoea, hyperandro-
genism and polycystic ovaries on ultrasound [29,30].
Associated endocrine features for PCOS included ele-
vated LH [31], which is strongly associated with infer-
tility (p = 0.0003) [32] and miscarriage [33] and elevated
fasting glucose which is prevalent in approximately 31% of
women with PCOS including normal weight women [34].
Oligomenorrhoea was defined as menstrual cycle length
that extended beyond 35 days (day one being the first day
of menses). Amenorrhoea was defined as no menstrual
period for three to six months or more [19]. This review
was focussed on hypothalamic, pituitary and ovarian
causes of menstrual irregularity with associated elevated
gonadotropins including LH and prolactin and arrested
folliculogenesis typically observed in polycystic ovaries.
Hyperprolactinaemia is usually considered a unique cause
for oligo/amenorrhoea; however in the present case it was
included due to the potential co-existence for elevated
prolactin, LH and PCOS, [32,35].
Hyperandrogenism was defined as clinical or bioche-
mically excessive androgens. Clinical markers in females
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acne, hirsutism and/or male pattern alopecia. Biochemical
indications include elevated plasma concentration of
androgens.
We conducted two searches. The first was sensitive and
aimed to capture all pre-clinical studies explaining the re-
productive endocrine effects of whole herbal extracts in
PCOS or associated oligo/amenorrhoea and hyperandro-
genism. The second search was specific and sought only
clinical studies investigating herbal medicines revealed
during the first search (for which a mechanism of effect
had been demonstrated). We additionally searched, on a
case by case basis for pre-clinical evidence for herbal med-
icines identified during the second search, but not in-
cluded in the results of the first search. Clinical studies
were excluded based on the absence of evidence for a
mechanism of effect for the whole herbal extract in repro-
ductive endocrinology associated with PCOS, oligo/amen-
orrhoea and hyperandrogenism. We used this approach to
improve transparency and to limit confirmation bias for
herbal medicines favoured by the authors in clinical
practice.
The first search revealed ten herbal medicines with a
demonstrated mechanism of reproductive endocrino-
logical effect for the whole herbal extract in PCOS,
oligo/amenorrhoea and hyperandrogenism. These were
Cimicifuga racemosa, Cinnamomum cassia, Curcuma
longa, Glycyrrhiza spp., Matricaria chamomilla, Mentha
piperita, Paeonia lactiflora, Silybum marianum, Tribulus
terrestris and Vitex agnus-castus. Herbal medicines with
a demonstrated mechanism of effect were entered as key
terms in the second search.
We searched the following electronic databases: the
Cochrane Library, MEDLINE ovidSP, CINAHL (1936 to
present), SciVerse, EMBASE, PubMed, from the date of
database inception to June 2014. In addition, we manually
searched bibliographies of review articles.
Key terms for the first search included: title or abstract
CONTAINS ‘herbal medicine’ OR ‘herbal extract*’ OR
‘phytotherapy’ OR ‘botanical’ AND title or abstract CON-
TAINS ‘androgen*’ OR ‘oestrogen*’OR ‘follicle stimulating
hormone’ OR ‘luteinising hormone’ OR ‘prolactin’ OR
‘insulin’ OR ‘glucose’ OR ‘polycystic ‘ovar*’. Search terms
for the second search included the following key words in
the title or abstract, CONTAINS; ‘menstrual irregularity’
OR ‘oligomenorrhoea’ OR ‘amenorrhoea’ OR ‘hyperandro-
genism’ OR ‘hirsutism’ OR ‘acne’ , OR ‘polycystic ovary
syndrome’ OR ‘PCOS’ OR ‘polycystic ovar*’ OR ‘oligo-
ovulation’ OR ‘anovulation’ OR ‘fertility’ OR ‘infertility’
OR ‘pregnancy’AND ten herbal medicines identified from
the laboratory search; ‘Cimicifuga racemosa’ OR ‘Cinna-
momum cassia’ OR ‘Curcuma longa’ OR ‘Glycyrrhiza ‘ OR
Matricaria chamomilla OR ‘Mentha piperita’ OR ‘Paeonia
lactiflora’ OR ‘Silybum marianum’ OR ‘Tribulus terrestris’OR ‘Vitex agnus-castus’. Truncation was used to capture
plural key words and synonyms, and acronyms were used
for some hormones (FSH and LH).
Our laboratory search included investigations into the
effects of herbal medicine using computer models, cell
cultures, animals with PCOS induced with oestradiol
valerate and androgens and sterilised and ovariectomised
rats. We excluded laboratory studies which commenced
using isolated chemicals not directly extracted from
crude herbal medicines and studies examining androgen
effects in male animals.
Our second search for clinical trials was performed with-
out language restriction and included randomised con-
trolled trials, non-randomised, open label and single arm
clinical trials. We included clinical studies investigating
commercially available herbal extracts and investigations
that compared the effectiveness of herbal medicine with
pharmaceuticals. We excluded clinical studies investigating
herbal medicines with unrelated outcomes (including pre-
menstrual syndrome, endometriosis and mastalgia) and
clinical studies examining the effectiveness of complex
herbal formulas for PCOS and associated oligo/amenor-
rhoea and hyperandrogenism, without demonstration of a
mechanism of effect for the whole complex formula. We
compared data from laboratory and animal studies with
the outcomes of clinical trials. Clinical studies were
assessed for risks of bias at study and outcome levels with




Our search identified 33 laboratory (pre-clinical) studies
(Figure 1). Eighteen studies met the inclusion criteria, nine
reported on receptor binding assays or ovarian or pituitary
(brain) cell cultures, [36-44] and nine used an animal experi-
mental model with hormone assays and/or post-mortem
examination of ovarian, uterine and brain histology, [45-53]
(Table 1). We excluded 15 studies for the following reasons;
investigation of effects in male animals (n = 4) and investiga-
tions which commenced with constituents that were isolated
from herbal medicines (n = 5). Six studies were excluded
due to no clinical evidence found (n = 6).
Clinical studies
Following the electronic and manual searches of bibliog-
raphies, forty six clinical studies were identified for inclu-
sion/exclusion assessment (Figure 1). A pre-requisite for
the inclusion of clinical studies was identified laboratory
evidence explaining the mechanism of effect in reproduct-
ive endocrinology. Fifteen met the inclusion criteria
[54-68]. Eight were randomised controlled trials (RCTs)
including 762 women [61-68] (Table 2). Thirty one studies
were excluded for the following reasons; investigation of
Table 1 Summary of evidence for the reproductive endocrinological effects of six herbal medicines in oligo/amenorrhoea, hyperandrogenism and PCOS
Herbal medicine Evidence Physiological effects in menstrual
irregularity (oligo/amenorrhoea),
hyperandrogenism and/or PCOS.
Botanic name Pre-clinical in vitro and in vivo Clinical RCTs (detailed in Table 2)
Herbal extract
Vitex agnus-castus Eight studies investigated gonadotropic hormone
concentration effects of Vitex agnus-castus.
Three RCTs investigate clinical effectiveness for Vitex
agnus-castus for oligo/amenorrhoea and PCOS
[61,62,64]. One RCT demonstrated equivalence for





1. Investigation for equivalence of dopaminergic effects for
Vitex agnus-castus and the pharmaceutical Lisuride using
rat pituitary cell cultures (basal and stimulated cells) [41]
1. Lowers prolactin due to dopaminergic
effects [38-41,63]
2. Brain (calf, guinea pig and rats) receptor tissue cultures
including DA2, histamine and 5HT transporters. Radio
ligand and super-fusion experiments [40]
2. No change for serum prolactin [64]
3. Three investigations found affinity for Vitex agnus-castus
and β oestrogen receptors [38,43,69]
3. FSH no change [39]
4. Using recombinant human dopamine (DA2) receptor
proteins [38]
4. LH no change [39]
5. The affinity of Vitex agnus-castus extract (with and without
fatty acids) for human μ opoid receptor cells cloned and
transfected into hamster ovary cells [70]
5. LH lowered [49]
6. The endocrine effects for Vitex agnus-castus were
investigated in normal and ovariectomised rats [49]
6. Binds to β oestrogen receptors
[38,43,69]
7. Corpus striatum membrane including D2 receptors to
assess the inhibitory properties of Vitex agnus-castus on
prolactin, FSH and LH [39]
7. Increased serum oestradiol [49,64]
8. Increased serum progesterone [49,62]
9. Improved pregnancy rates [61,62]
Cimicifuga racemosa Four laboratory studies investigated pituitary oestrogen
receptor binding and gonadotropin concentrations
following exposure to Cimicifuga racemosa.
Three RCTs demonstrate positive fertility effects for
Cimicifuga racemosa in women with PCOS [65,67,68]
Ethanol extract
Klimadynon® 1. One study investigated a constituent flavonoid of Cimicifuga
racemosa, discovered during the course of the study for
reduction for LH in ovariectomised rats [37]
1. Binds with α oestrogen receptors [44]
in the pituitary and reduces LH
secretion [45,52,68].
2. Oestrogen receptor binding affinity for Cimicifuga
racemosa was studied using pituitary cell cultures from
ovariectomised rats. This study followed a clinical study
demonstrating significantly lowered LH in post-
menopausal women following administration of
Cimicifuga racemosa (2 mg for two months) against
placebo control (n = 110) [45]
2. Increases luteal progesterone
concentration [65,67,68]
3. Binding affinity for oestrogen receptors (ERα) for Cimicifuga
racemosa examined using MCF7 cell cultures [44]
3. Improves endometrial thickness for
infertile women with PCOS [65,67,68].
4. Chronic and acute dosage effects of Cimicifuga racemosa
and oestradiol on oestrogen receptors, gene expression,
uterine and bone tissue of ovariectomised rats [52]
4. Lowers LH in women with PCOS
[65,67,68]
5. Improves FSH:LH ratio for women with
PCOS [67]
6. Limits anti-oestrogen effects when
used in combination with Clomiphene

























Table 1 Summary of evidence for the reproductive endocrinological effects of six herbal medicines in oligo/amenorrhoea, hyperandrogenism and PCOS
(Continued)
Cinnamon cassia One animal study compared the effectiveness of
Cinnamomum cassia with metformin against controls in rats
with PCOS. Hormone concentration was measured at 15
and 30 days [48]
One pilot RCT demonstrated positive effects for
metabolic parameter’s (HOMO and QUICKI) for
Cinnamomum cassia in overweight women with
PCOS [66]
1. Equivalence for metformin for reduced
testosterone in PCOS [48]
Aqueous extract (animal study)
2. Equivalence for metformin for reduced
LH in PCOS [48]Ethanol extraction (Human
trial)
3. Equivalence for metformin for reduced
LH in PCOS [48]
4 Equivalence for metformin for reduced
insulin resistance [48]
5. Improved metabolic profile for
overweight women with PCOS [66]
Herbal medicine Evidence Physiological effects in oligo/
amenorrhoea, hyperandrogenism
and/or PCOS
Pre-clinical in vitro and in vivo Data from clinical studies (non RCTs)Botanic name
Herbal extract
Tribulus terrestris Three animal studies investigated the effects of Tribulus
terrestris, two for polycystic ovaries and one on oestrogen
sensitive tissues in rats.
Two clinical studies
Ethanol extracts 1. One study examined the oestrogenic effects of Tribulus
terrestris on uterine and vaginal tissue of ovariectomised
rats [51].
1. Healthy women n = 8 early menstrual cycle
(follicular phase) Pre and post serum hormone
concentration for FSH, LH testosterone and
oestradiol at 8 am and 12 pm. Intervention
consisted of Tribulus Terrestris 250 mg per day
over five days. Results showed significant
increase in FSH and rise in LH (not significant),
an increase in oestradiol and no change in
testosterone concentration [56]
1. Ovulation induction in polycystic
ovaries [46,47].
2. Two studies investigated the ovulation rates, number of
corpus luteum and follicle characteristics in rats with
polycystic ovaries following exposure to various doses of
Tribulus terrestris [46,47].
2. Equivalence of Tribulus terrestris and three
ovulation induction pharmaceuticals evaluated
ovulation in women with oligo/anovular
infertility (n = 148) [60].G
2. No oestrogenic effects in female
reproductive tissues [51].
3. Increased FSH in healthy women [56].
4. Equivalence for ovulation induction
for Tribulus Terrestris and Clomiphene




Two preclinical studies investigated the effects of Glycyrrhiza
spp. for steroid hormone concentration and in polycystic
ovaries.
Two clinical trials
1. Steroid hormone concentration in sterilised and
oophrectomised rats following exposure to Glycyrrhiza spp.
(kanzo) [53].
1. Single arm clinical trial investigating serum
androgen concentration in healthy women
aged 22–26, (n = 9) following administration of
Glycyrrhiza spp. 7grams per day [55].
1. Increased aromatisation of testosterone
to 17 beta oestradiol shown by
significantly dose dependent reduced
testosterone and increased oestradiol [53].Glycyrrhiza uralensis (Chinese
liquorice)
Ethanol extract
Aqueous extract used in two
pre-clinical studies 2. Morphological features of polycystic ovaries of rats following
exposure to two Chinese herbal compounds with only
Glycyrrhiza spp. as a common ingredient [50].
2. Single arm clinical trial including women with
PCOS (n = 32) taking Spirinolactone [54].
2. Reduced free and total testosterone [53].
3. Reduced serum androgens in healthy
women [55].
4. Reduced androgen flare for women
with PCOS using the anti-androgen
pharmaceutical Spirinolactone [54].
































One laboratory study examined the effects for the combination
Paeonia lactiflora and Glycyrrhiza uralensis on testosterone, oestradiol,
FSH and LH in sterilised female rats [53].
Two single arm clinical trials examined androgen
concentrations Following treatment with Paeonia
lactiflora and Glycyrrhiza uralensis in the Chinese
herbal combination Shakuyaku-kanzo-to. One
included infertile oligomenorrhoeic women with
hyperandrogenism (n = 8) [58] and the other
included women with oligo/amenorrhoea and
PCOS (n = 34) [59].
1. Reduced total and free testosterone
[53,58,59].
2. Increaed SHBG [59].
3. Reduced LH [53].
4. Reduced LH:FSH ratio [59].
5. Oestradiol slight increase (not significant) [53].






Paeonia lactiflora and Cinnamomum cassia combination was
investigated for steroid hormonal effects on cultured human
granulosa cells (obtained from women undergoing IVF). Cells were
incubated with different doses for 48 hours [42]
One clinical trial investigated the effects of Paeonia
lactiflora and Cinnamomum cassia combination
(Unkei-to) [57]. This single arm study included
amenorrheic women aged 17–29 years (n = 157)
with a sub group of women with hyper-functioning
oligo/amenorrhoea (n = 42). Ovulation occurred in
61.3% of primary amenorrheic women and in 27.3%
of secondary amenorrheic women following two
months of treatment [57].
1. Increased granulosa production of
oestradiol [42].
2. Increased granulosa production of
progesterone [42].
3. Reduced LH in oligo/amenorrhoea [57].































Subjects Intervention Outcome measures Results and level of significance Comments
Kilicdag [63] Randomised comparative
effectiveness trial.
Eighty women, 40 with
hyperprolactin-aemia,
40 with cyclical mastalgia.
Herbal extract Vitex agnus-castus





and Bromocriptine for serum
prolactin concentration on
days 5–8 of the menstrual cycle.
Mean prolactin concentration before
and after in the V.agnus-castus arm;
946mIU/L (±173.5) to 529mIU/l (±279.7),
p < 0.0001. In the Bromocriptine arm;
885.0 mIU/l (±177.5) to 472.68mIU/L
(±265.6), p < 0.0001.
All participants completed the
trial. Adverse reactions; zero
reported in V. agnus-castus
group; 12.5% of participants
reported adverse reactions in
the Bromocriptine group
(nausea and vomiting).
Treatment for 3 months.
1 tablet per day. Bromocriptine
in the form of Parlodel produced
by Novartis, Turkey, 2.5 mg twice
daily.
Normal range 25.2mIU/l -
628.5 mIU/l.
Equivalence demonstrated for the
significant reduction of serum
prolactin for V. agnus-castus and
Bromocriptine (P = 0.96).
Small sample sizes with 2 sub-
groups. Insufficiently powered
to correctly identify the effects;





















clinical parameters in 57.6% of
women in treatment group versus
36.0% in placebo group, P = 0.069.
Numbers too small for statistical
significance in clinical outcomes.
Three months. Follow up
at 2 years
Secondary amenorrhoea,
n = 38; luteal insufficiency,
n = 31; idiopathic infertility,
n = 27.
30 drops per day over 3 months.
Hormonal data from 32 cases.
In the third treatment month
66 complete data sets were
available.
In a subgroup of women with luteal
insufficiency (n = 21) there were
significant improvements in clinical
parameters in the treatment group
compared to placebo (p = 0.023).
Preparation ‘Mastodynon’ contains
V agnus-castus plus other herbal
extracts which may have
confounded outcome measures.
Mastodynon® additionally contains
herbal extracts of Caulophyllum
thalictroides, Lilium majus, Cyclamen,
Ignatia and Iris.
Reasons were as follows;
4 due to drug reactions
and 15 due to pregnancy.
15 women conceived in the treatment
group compared to 8 in placebo group
in the first 3 months (while women
were treated).
Inconsistencies in data assessment
include the recommendation for
treatment with Mastodynon over
3–6 months yet it was tested
for 3 months.No evidence that therapeutic
agents additional to V. agnus-castus
in Mastodynon® affect prolactin
concentration.
Four withdrew for unknown
reasons.
All pregnant women were withdrawn
from the study. 4 women had
miscarriages, all in the active arm.
After 2 years there were 21 more
pregnancies with 2 miscarriages – evenly
spread over active and placebo groups.
Women with infertility were
included in this study however
data from women who conceived
were excluded. This may have led
to an underestimation of treatment






study. Three months or
3 menstrual cycles.
Women with fertility
disorders, (n = 67). Two
sub-groups.
Herbal extract Phyto-Hypophyson®
by Steril-Pharma GmbH Herrsching,
Germany; contains Vitex agnus-castus
plus Chelledonium majus and
Silybum marianum (St Mary’s thistle)
in homeopathic form. Additional
herbal extracts have reported activity
in hepatic function. There are no
reports for direct reproductive effects.





Oligomenorrhoeic subgroup - clinical
outcomes were significantly improved
in the treatment arm at 82% compared
to 45% in placebo arm P= 0.021. When
the amenorrheic group were included
in analysis, differences were not
significant p = 0.19.
Diagnosis for anovulatory
amenorrhoea is not well
described. Non-statistically
significant take home baby
rates were complicated by
insufficient sample size. 366
patients are required to have
a 95% chance, as significant
at the 5% level, an increase
in take home baby rates from
6% in the placebo group to
18% in the experimental
group. The authors conclude
that this preparation may be
useful if given 3–6 months,
yet they only tested for
3 months.
1.oligomenorrhoea,
n = 37 For progesterone <1 ng/mL:
an increase to >5 ng/mL
at the end of 3rd cycle
Mid luteal progesterone concentration
in oligomenorrhoeic sub-group was




cycle of at least 4 days.
Earlier ovulation of at






pregnancy rates and take
home baby rates.
At 6 months following conclusion of
treatment, the take home baby rate
with treatment was 18.7% compared





































cycle length, height (cm)
and weight (kgs) and
randomised. Baseline
differences between
arms were not significant
p = 0.63, p = 0.48 and
p =0.37 respectively. 37
complete case reports:
Treatment arm n= 17,
placebo n= 20.
Vitex agnus-castus extract 20 mg
in the commercial preparation of
Strotan® Hersteller: Pharma
Stroschein GmbH, Hamburg,
Germany. 1 capsule per day or
placebo.
Serum prolactin concentration
at 15 and 30 minutes following
intra venous TRH (200mcg)
stimulation. Luteal phase length,
number of days. Measurements
on menstrual cycle days 5 to
8 and 20 for FSH, LH, oestradiol,
progesterone, DHEAs, thyroid
stimulating hormone (TSH), T3,
T4, testosterone.
No significant changes in prolactin
before and after in either group.
In this study 52 women were
eligible to participate, statistical
analyses were performed on
data from 37 women.
Length (number of days) of the
luteal phase before and after;
treatment group 3.4 (±5.0) to
10.5 (±4.3) (p < 0.005), placebo
3.4 (±5.1) to 5.5 (±5.2), p = 0.22.
There is missing data due to
the presence of luteinised,
unruptured follicles (9 women).
These data were not included
in analyses. Six women did not
present for further investigation.
Mid luteal (day 20) serum
progesterone concentration
before and after; treatment
arm 2.46 (±0.70) to 9.69
(±6.34), p < 0.001. Placebo
1.99 (±0.65) to 2.34 (±0.59)
p = 0.08.
No description of the
distribution of drop-outs




and a possible over-
exaggeration for
treatment effect.
Mid-cycle oestradiol; treatment arm
131.6 (±25.0) to 151.6 (±25.4), p < 0.05.
Placebo: 119.5 (±26.0) to 131.1 (±33.2)
p = 0.22. Pregnancies in treatment
group n= 2.




fertility status, duration of
latent hyperprolactinaemia.
Shahin et al. [65] Randomised controlled
trial using with an




147 women aged less






(n = 28). Anovulation was
diagnosed by serum
oestradiol < 200 ng/ml
and absence of a dominant
ovarian follicle on day 9
of the menstrual cycle.
Complete data sets
available for 119 women.
All women received Clomiphene
citrate (clomiphene) 150 mg on
menstrual cycle days 3–7. A
randomised group also took
Cimicifuga racemosa 20 mg per day
between days 1–12. Cimicifuga
racemosa described as
‘phytoestrogens’ was provided in
the commercial preparation
Klimadynon®, manufactured by
Norica in Germany. A trigger
injection (human chorionic
gonadotropin, 10 000 IU) and timed
intercourse was recommended
when a dominant follicle > 17 mm
was observed.
Pregnancy rate measured
as increasing serum human
chorionic gonadotropin
(HCG) over two days. Clinical
pregnancy defined as






Number of days to ovulation
(trigger injection) Serum
concentration for FSH
oestradiol and LH. Luteal
progesterone measured on
days 21–23 of the menstrual
cycle. Miscarriage and multiple
pregnancy rates.
Pregnancy rate in clomiphene alone
group was 20.3% and 43.3% in the
clomiphene plus Cimicifuga racemosa
group (P < 0.01). Clinical pregnancy
rate in the combination group was
36.7% versus 13.6% in the clomiphene
alone group (P < 0.01). Endometrial
thickness in combination group was
8.9 (±1.4) versus 7.5 (±1.3) (p < 0.001).
Days to ovulation in clomiphene
alone group was 13.0 ± 1.1 and in
the clomiphene plus Cimicifuga
racemosa group 14.2 ± 1.3 (n.s.). Luteal
progesterone peak (ng/ml) in
combination group was 13.3 (±3.1)
versus 9.3 (±2.0) in clomiphene alone
group (p < 0.01). All other hormone
measures were not significantly
different
No detailed current baseline
criteria for other causes of
infertility. Confounding factors
include current male fertility
status. This may have caused
an imbalance between the
two groups. There is no



























Table 2 Summary of randomised controlled trials for five herbal medicines in oligo/amenorrhoea, hyperandrogenism and PCOS (Continued)
Kamel [67] Randomised controlled




women with PCOS. Three
menstrual cycles.
Women aged 21–27 with
primary or secondary
infertility. Diagnosis of
PCOS by ultrasound and
clinical history (n = 100).
Gynaecology outpatient
clinic. Two groups. Group
one (n = 50) received
Clomiphene citrate
100 mg days 2–7 of the
menstrual cycle; group
two (n= 50) received
20 mg Cimicifuga racemosa




Neumarkt i.d. OBF Germany.
20 mg twice daily days 2–12 of
menstrual cycle Clomiphene
citrate (clomiphene) 100 mg
daily for days 2–7 of menstrual




follicle (>18 mm) was observed
on ultrasound.
Serum measurements during
follicular phase for FSH, LH and







Positive outcomes for Cimicifuga
racemosa compared to clomiphene
for reduced day 2–5; LH (p = 0.007)
and improved FSH to LH ratio
(p = 0.06), mid luteal progesterone
(p = 0.0001), endometrial thickness
(p = 0.0004). Pregnancy rates were
higher in the Cimicifuga racemosa
group (7/50 compared to 4/50) but
not statistically significant (p = 0.1).
Adverse events (4 women) and twin
pregnancy’s (two women) were
not significantly different between
groups.
No detail for diagnostic criteria
for PCOS. Confounding fertility
factors not described. Drop-out
reasons were not reported
seven in Cimicifuga racemosa





Women with PCOS and




150 mg on days 3–7 of cycle);
trigger injection (HCG 10000 IU
Pregnyl), timed intercourse and
progesterone support (oral
micronized progesterone). A
randomly selected group additional




Pregnancy rates were 33 out of 192
cycles (17.2%) for the clomiphene
alone group and 71 out of 204 cycles
(34.8%) for the clomiphene plus
Cimicifuga racemosa group.
Non-blinding compromised the
internal validity of the findings in
this study. Confounding variables
include variations in participant’s
and clinicians attitudes and may
have led to differences which were
unaccounted for between the two
groups. However the outcomes
are objective with a statistically
powered sample size.
Three menstrual cycles
each separated by two
months of no treatment.
Two groups matched for
demographics, age, BMI,
primary and secondary
infertility and duration of
infertility (months).
Treatment arm n= 96,
control n = 98.
1. Number of days to ovulation
(trigger injection). Follicular
maturation monitored by
ultrasound. Number of days to trigger
injection was 15 (±1.7) for the
clomiphene alone group and
12.0 (±1.9) in the clomiphene
plus Cimicifuga racemosa
group (p = 0.01) Measures for miscarriages are
based on per cycle are not valid.
Miscarriages per pregnancy are
of greater relevance.
Randomisation for 206
women 12 were excluded
due to failure to respond
(treatment group n= 7,




Endometrial thickness in the
clomiphene alone group was
8.5 mm (±1.9) compared to
12.9 (±2.3) in the clomiphene
plus Cimicifuga racemosa
group (p < 0.001).
The miscarriage rate per pregnancy
for the clomiphene alone group
was 5 out of 33 (15.2%) and 6 out
of 71 (8.5%) in the clomiphene plus
Cimicifuga racemosa group.
3. Serum hormones during
follicular phase oestradiol,
LH and FSH. Luteal
progesterone measured
day 21–23 of the cycle.
Serum LH was 8.0 (±0.9) in the
clomiphene group and 5.7
(±0.9) in the clomiphene plus
Cimicifuga racemosa group
(p < 0.001) and oestradiol was
228.3 (±30.2) in the clomiphene
alone group and 299.5 (±38.9) \in
the clomiphene plus Cimicifuga
racemosa group (p = 0.01)
4. Pregnancy outcomes
for early miscarriage.
Miscarriages were 5 out of 192
cycles in the clomiphene group
































trial (pilot). Eight weeks.
15 overweight women
with oligo/amenorrhoea
and polycystic ovaries on
ultrasound. Mean body
mass index 28.8 ± 1.3 kg/m2.
Mean age 31.1 ± 2.0 years
Cinnamomum cassia extract 333 mg
(Integrity Nutraceuticals International
Sarasota, Florida) or placebo. One














(QUICKI) in the treatment
group. 0.35 to 0.38, (7.7%)
p < 0.03. Insulin resistance
(HOMO-IR) significantly
reduced in treatment group
2.57 to 1.43 (44.5%) p < 0.03.
Controls no change insulin
sensitivity or insulin resistance.
No change in either group for
BMI, testosterone and oestradiol.
Differences between Cinnamomum
cassia group and normal weight
and ovulatory controls were not
significant. (P < 0.17). No reported
adverse reactions.
Small pilot study, the authors report
that larger studies are required to
confirm findings. Small sample size
may explain non-significant
comparison with normal weight
and ovulating women.
Reproductive outcomes were
unchanged in this study however



























Records identified through 
database searching
(n = 66)
Additional records identified 
through bibliography searches
(n = 14)




(Pre-clinical studies n = 33
Clinical studies n = 46)
Full-text articles assessed for 
eligibility
(Preclinical studies n=26
Clinical studies n=39) 
Pre-clinical full-text studies excluded
(total 8) for the following reasons; no 
clinical evidence (n=6), investigation of 
isolated herbal chemicals (n=2). 
Clinical full-text studies excluded (total 
24) for the following reasons; outcomes  
other than oligo/amenorrhoea,  
hyperandrogenism or PCOS (n= 13); no  
pre-clinical evidence(n=11).
Studies included in 
qualitative synthesis
Pre-clinical studies n = 18
Clinical studies n=15
Pre-clinical studies excluded (total7) for
the following reasons;investigation of 
effects in male animals (n=4) and study
commenced with isolated herbal 
chemicals (n=3).
Clinical studies excluded (total 7) for the
following reasons; investigated isolated 
herbal chemicals (n = 3), including male
subjects (n=4). 
Figure 1 Flow Chart. Overarching results from two searches; preclinical data and clinical outcomes
Arentz et al. BMC Complementary and Alternative Medicine 2014, 14:511 Page 11 of 19
http://www.biomedcentral.com/1472-6882/14/511isolated herbal chemicals (n = 3); inclusion of male sub-
jects (n = 4); no pre-clinical evidence (n = 11) and condi-
tions different to those specified (n = 13).Excluded studies
Details of excluded studies investigating herbal medi-
cines with clinical evidence but no preclinical evidence
were provided in Table 3. Herbal medicines with pre-
clinical evidence but no clinical evidence were pro-
vided in Table 4, and investigations into isolated
chemicals derived from herbal medicine were pre-
sented in Table 5.
Seven RCTs examined commercially produced
herbal medicine extracts. These were Vitex agnus-
castus in the form of Strontan®[64], Mastodynon®[61],
Phyto Hypophyson®[62] and Agnacaston®[63] and
Cimicifuga racemosa in the form of Klimadynon®
[65,67,68] (Table 2).Herbal medicines with effects in oligo/amenorrhoea,
hyperandrogenism and PCOS
The results of preclinical studies and clinical studies
have been summarised together for each of the six
herbal medicines.Vitex agnus-castus
Pre-clinical and clinical evidence was found for Vitex
agnus-castus for lowered prolactin, improved menstrual
regularity and treatment of infertility. Vitex agnus-castus
contains a variety of compounds which bind to dopa-
mine type 2 (DA-2) receptors in the brain; reduce cyclic
adenosine mono phosphate (cAMP) and lowered prolac-
tin secretion (Table 1). This was demonstrated in studies
using recombinant DA-2 receptor proteins, and basal
and stimulated rat pituitary cell cultures [38-41]. Prolac-
tin lowering effects were found in normal and ovariecto-
mised rats [49]. Additional agonistic opiate effects were
Table 3 Herbal medicines with clinical evidence not included in this review
Herbal medicine Clinical evidence (or potential) for PCOS and associated
oligo/amenorrhoea or hyperandrogenism
Reason for non-inclusion – insufficient pre-clinical evidence
for mechanism of effects for whole herbal extract
Camellia sinensis
(green tea)
Hormone concentration in obese women with PCOS [71]. Isolated constituent (epigallocatechin gallate 1) examined
[72]. No evidence found for effects for whole herbal extract
in PCOS, oligo/amenorrhoea and hyperandrogenism.
Mentha spicata
(spearmint tea)




Metabolic hormone management for type two diabetes [75]. No evidence for mechanism of effect in PCOS, oligo/




Ovulation rates in PCOS [76]. No evidence for mechanism of effect in PCOS, oligo/




Menstrual regulation [77,78] and hormonal concentration [78-80]
in post-menopausal women.




Anti-androgen effects in prostatic hypertrophy [81]. No evidence for mechanism of effect found in PCOS, oligo/




Anti-androgen effects in chronic pelvic pain and prostatitis [82-84]. No mechanism of effect in PCOS, oligo/amenorrhoea or
hyperandrogenism (in female cell cultures or animals).
Silybum marianum
(St Mary’s thistle)





Evidence for improved uterine bleeding (including
oligomenorrhoea and amenorrhoea) in women with PCOS
comparable with Medroxyprogesterone acetate [86].
No mechanism of effect studies found for whole herbal




Anti-androgen effects in women [87]. Anti-androgen effects through interaction with SHBG in
prostate cells [88-90]. Anti-inflammatory and anti-nociceptive
effects [91] No evidence for effects of Urtica dioca in female
cell cultures or animals.
Other excluded studies investigated the herbal medicines included in this review examining conditions other than PCOS, oligo/amenorrhoea and
hyperandrogenism. These included investigations into effectiveness for Vitex agnus-castus for pre-menstrual syndrome [92-97] and mastalgia [98,99], Cimicifuga
racemosa for menopausal symptoms [100] and Glycyrrhiza spp with Paeonia lactiflora libido in males [101].
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cultures [70].
Clinical equivalence for prolactin lowering effects of
Vitex agnus-castus (Agnucaston® 40 mg per day) and the
pharmaceutical Bromocriptine (Parlodel® 5 mg per day)
was found in one study including 40 women with hyper-
prolactinaemia [63]. Mean concentrations for prolactin
following three months treatment with Vitex agnus-
castus was significantly reduced from 946 mIU/l (±173)
to 529 mIU/l (±297) (p < 0.001). Comparatively, meanTable 4 Herbal medicines with pre-clinical evidence not inclu
Herbal medicine Pre-clinical evidence for (potential) effects in rep










Anti-androgen effects in animals [104].
Silybum marianum
(St Marys thistle)
Anti-proliferative antioxidant and biochemical effect
Studies investigating chemical compounds derived from the herbal medicines, inclu
agnus-castus [70] and Cimicifuga racemosa [106].prolactin concentration in the Bromocriptine group was
significantly reduced from 885 mIU/l (±178) to 473 mIU/l
(±266) (p < 0.001) demonstrating that both treatments
were effective treatment for women with hyperprolacti-
naemia (normal reference range 25-628 mIU/l). The mean
difference in prolactin reduction of the two groups was
not significant (p = 0.96) (Table 2).
Positive effects for Vitex agnus-castus in oligo/amen-
orrhoea and infertility was demonstrated in three pla-




No clinical evidence examining
effectiveness in women was found.
morphology in animals with No clinical data found.
No clinical data for women.
s in the liver [105]. No clinical evidence including women
was found.
ded in this review but investigating different outcomes were found for Vitex
Table 5 Chemicals derived from herbal medicines not
included in this review
Isolated chemicals Evidence for effects
Phytoestrogens Hormonal effects in ovarian granulosa cells [107].
Berberine Comparison with metformin in PCOS [16];
ovarian theca cell hormone production [108].
Catechin derived
from Camellia sinensis












Selective oestrogen receptor activity
(competitive inhibition via beta oestrogen
receptors) [36].
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menstrual cyclicity was significantly improved for women
treated with Vitex agnus-castus (Mastodynon® 30
drops per day for three months) compared to placebo
(p = 0.023) [61] (Table 2). Another study, including
women with sub fertility (n = 67), showed improved
menstrual cyclicity for a sub-group of women with oli-
gomenorrhoea following treatment with Vitex agnus-
castus (Phyto-Hypophyson® 7.5 ml per day) compared
to placebo, (p = 0.023) [62] (Table 2). A third study in-
cluding women with hyperprolactinaemia (n = 37)
demonstrated improved menstrual cyclicity by an in-
creased average number of luteal days from 3.4 days
(±5.0) to 10.5 days (±4.3) (p < 0.005) following treat-
ment with Vitex agnus-castus (Strotan® 20 mg per day)
for three months. The placebo group reported average
number of days in the luteal phase was 3.4 (±5.1) at
baseline and 5.5 (±5.2) at three months, which was not
significant (p = 0.22) [64] (Table 2). Methodological
shortcomings included not reporting baseline charac-
teristics for subgroups and small sample sizes; how-
ever clinical outcomes demonstrated physiological
effects consistent with laboratory and animal findings
(Tables 1 and 2).
Cimicifuga racemosa
Cimicifuga racemosa was found to lower LH in two la-
boratory studies both examining cell cultures from ovar-
iectomised rats [45,52] (Table 1). The mechanism
occurred through competitive inhibition of oestrogen
following the selective binding of oestrogen receptors
(ERα) on the hypothalamus and pituitary [52]. An earlier
study found contrary results for reduction of LH, how-
ever this study investigated an isolated flavonoid and
suggested that other constituents may be active [37].
Three RCTs corroborate the positive fertility effects for
Cimicifuga racemosa in women with PCOS, used inconjunction and when compared with the pharmaceutical
Clomiphene citrate (clomiphene), [65,68,71] (Table 2). Re-
sults were reported for 441 women and show improved
pregnancy rates when Cimicifuga racemosa was added to
clomiphene during one menstrual cycle. In a study includ-
ing women with PCOS (n = 147), pregnancy rates for the
group receiving combined therapy (clomiphene 150 mg
plus Cimicifuga racemosa 20 mg per day (Klimadynon®))
were 43.3% compared to 20.3% for women receiving only
clomiphene [65] (Table 2). In another study using similar
methodology (n = 100) pregnancy rates were 34.8% for the
group treated with Cimicifuga racemosa plus clomiphene
compared to 17.2% for women treated with clomiphene
alone [68] (Table 2). Another study included women with
PCOS and infertility (n = 100) compared Cimicifuga race-
mosa (Klimadynon®) and clomiphene over three months
for hormone concentrations and pregnancy rates. Preg-
nancy rates were higher in the women in taking Cimicifuga
racemosa compared to clomiphene, 14% and 8% respect-
ively; however differences were not statistically significant.
This study found significant effects for lowered luteinising
hormone for women with PCOS receiving Cimicifuga race-
mosa compared to clomiphene (p = 0.007) [67]. Findings
from clinical studies concur with laboratory and animal
studies; however potential risks for bias include per-
formance and collection bias due to lack of blinding
(Table 2).
Tribulus terrestris
Two laboratory based RCT’s examined the effects of
Tribulus Terrestris in rats with polycystic ovaries in-
duced with oestradiol valerate [46,47] (Table 1). Both stud-
ies demonstrate significantly improved ovulation rates for
animals treated with two doses of Tribulus terrestris
extracts compared to controls. Although the endocrino-
logical effects were not described in either study, labora-
tory findings of ovulation induction are supported by the
clinical findings of elevated FSH following treatment with
Tribulus terrestris [56] (Table 2).
A prospective, observational clinical trial examined the
endocrine effects of Tribulus terrestris 750 mg per day,
over five days in eight healthy women (aged 28–45). A
significant increase in mean serum FSH concentration
from 11 mIU/ml before treatment to 17.75 mIU/ml fol-
lowing treatment (P < 0.001) was demonstrated. Pre-
treatment FSH levels returned following cessation of
treatment (Table 1). Another clinical study evaluated the
equivalence of Tribulus terrestris (Tribestan®) and phar-
maceuticals for ovulation induction in women with
oligo/anovular infertility (n = 148), [60]. During the three
month follow up, ovulation rates were highest with epi-
mestrol (74%), followed by Tribulus terrestris (60%),
clomiphene (47%) and cyclofenil (24%). However, the
evidence for Tribulus terrestris should be interpreted
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study was uncontrolled with a small number of healthy
participants [56], the second study did not report base-
line characteristics, methods for allocation to treatment
groups and data were not statistically analysed [60]
(Table 1).
Glycyrrhiza spp
Androgen lowering effects for Glycyrrhiza spp. have
been demonstrated in one laboratory study examining
hormone concentration in female rats (Glycyrrhiza ura-
lensis), [53] and corroborated in two clinical trials, one
including healthy women [55] and the other including
women with PCOS (Glycyrrhiza glabra) [54] (Table 1).
The animal study reported significantly reduced free and
total testosterone and increased oestradiol in sterilised
rats and no hormonal changes in oophrectomised rats.
The authors conclude that the hormonal effects oc-
curred primarily in the ovary via enhanced aromatisation
of testosterone to 17-beta oestradiol. The investigators
also observed significantly increased oestradiol. There
were no changes to FSH or LH in androgen sterilised or
oophrectomised rats [53].
Another animal study examined the effects of Glycyrrhiza
uralensis on the morphological features of polycystic ovaries
using immunohistochemistry [50] (Table 1). This study
demonstrated significantly increased ovulation rates by
the number of corpus luteum in polycystic ovaries
compared with controls. The authors propose that the
mechanism of effect for Glycyrrhiza uralensis was com-
petitive inhibition of oestrogen at oestrogen receptor
sites, limiting the production of nerve growth factor
(NGF), its neurotropic effects and inhibition of sympa-
thetic neurological involvement in the pathogenesis of
polycystic ovaries.
Two clinical studies examined the androgen lowering ef-
fects of Glycyrrhiza Glabra. A single arm clinical trial
demonstrated reduced testosterone in healthy women
aged 22–26 years (n = 9) over two menstrual cycles. Treat-
ment with Glycyrrhiza glabra, 7 grams per day reduced
testosterone from 27.8(±8.2) to 17.5 (±6.4), p < 0.05 [55].
Another single arm clinical trial investigated the effects of
Glycyrrhiza glabra in women with PCOS, (n = 32). Glycyr-
rhiza glabra 3.5 g per day was added to anti-androgen
pharmaceutical treatment, Spirinolactone 100 mg/day
over two menstrual cycles. An unwanted side effect for
Spirinolactone was the flare of androgens during the initial
phase of treatment. This study demonstrated reduced
concentrations of testosterone during the first four days of
treatment at 103 ± 29 ng/d in the Spirinolactone group
compared to 91 ng/d (±19) when combined with Glycyr-
rhiza glabra (p < 0.05) [54] (Table 1). Consistent labora-
tory and clinical outcomes were demonstrated however
limitations included design shortcomings. Both clinicalstudies were open label observational design with small
sample sizes; one included healthy participants. Rigorous
studies are needed to confirm the androgen lowering ef-
fects of Glycyrrhiza spp. in hyperandrogenism and PCOS.
Results for Glycyrrhiza Spp. (and indeed any herbal in-
gredient) were complicated in this case by the variation in
herbal extraction processes and subsequent variability in
chemical profiles of the herbal ingredients. The laboratory
studies of the herbal material were based on aqueous ex-
tracts of crude material whilst the clinical studies were
based on ethanol extracts. Despite variability in the herbal
extraction methods, both laboratory and clinical studies
demonstrated anti-androgenic effects.
Paeonia lactiflora and glycyrrhiza uralensis
One laboratory study and two clinical investigations pro-
vided evidence for the two herb combination, Glycyrrhiza
uralensis and Paeonia lactiflora [53,58,59] (Table 1). An
animal study found significant reductions in free and total
testosterone following exposure to the combination [53]
(Table 1). These findings were supported in two open label
clinical trials including women with PCOS (n = 34) [59]
and women with hyperandrogenism (n = 8) [58]. Both tri-
als examined the effects on androgens for the aqueous
extract TJ-68 (equal parts Glycyrrhiza uralensis and
Paeonia lactiflora), 75 grams per day for 24 weeks and 5–
10 grams per day for 2–8 weeks respectively. In the trial
including women with PCOS, mean serum testosterone
was significantly reduced from 137.1 ng/dL (±27.6) to
85.3 ng/dL (±38), p < 0.001 at four weeks of treatment
[59]. Similar effects were observed in the women with oli-
gomenorrhoea and hyperandrogenism which showed
serum testosterone reduced from 50-160 ng/dL prior to
treatment to less than 50 ng/dL [58]. However statistical
significance was not reached due to the small sample size
despite positive outcomes in seven out of eight partici-
pants (Table 1).
Paeonia lactiflora and cinnamomum cassia
Paeonia lactiflora combined with Cinnamomum cassia
in a preparation called Unkei-to was investigated in an in-
vitro study for ovarian production of 17-beta-oestradiol
and progesterone, [42] (Table 1). Granulosa cells obtained
from women undergoing IVF were examined for steroid
hormone concentration following incubation with differ-
ent doses over 48 hours. Oestradiol was significantly in-
creased (p < 0.01) following exposure to doses of 0.3 ug/ml
of Unkei-to. Supporting clinical evidence was found in
one clinical trial of 157 infertile women aged 17–29 years,
including a subgroup of 42 women with hyper-
functioning (PCOS) oligo/amenorrhoea. Treatment with
Unkei-to, 7.5 grams per day for eight weeks, demonstrated
significant reductions of mean LH in the PCOS sub-group
of 49.7% (±15.3). Ovulation was confirmed in 30 out of 42
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however include findings based on sub-group compari-
sons without description of subgroup baseline characteris-
tics (other than oligomenorrhoea). Although the same
aqueous extract intervention was investigated in pre-
clinical and clinical studies, it contained additional herbal
extracts and it was irrational to attribute hormonal effects
to Paeonia lactiflora and Cinnamomum cassia.Cinnamomum cassia
An animal study compared the effectiveness of Cinnamo-
mum cassia and the pharmaceutical Metformin on hor-
mone concentration in rats with PCOS [48] (Table 1). Both
interventions demonstrated significant improvements com-
pared to controls at 15 days for measures of testosterone
ng/ml (control 0.747 ± 0.039; metformin 0.647 ± 0.027; Cin-
namomum cassia 0.625 ± 0.029); LH ng/ml (control 7.641 ±
0.267; metformin 6.873 ± 0.214; Cinnamomum cassia
6.891 ± 0.221) and insulin resistance (HOMA-IR) (control
10.018 ± 0.217; metformin 7.067 ± 0.184 Cinnamomum
cassia 8.772 ± 0.196) (p < 0.05) [48]. The metabolic effects
for Cinnamomum cassia were further demonstrated in
overweight women with oligo/amenorrhoea and PCOS in
a placebo controlled RCT [66] (Table 2). However, although
the RCT had low risks for bias, it was a pilot study primar-
ily investigating feasibility. Outcomes were promising for
metabolic profile in PCOS however the sample size was
small and the authors recommended further studies.Summary of results
This review includes 18 preclinical laboratory based stud-
ies and 15 clinical trials. We found reproductive endocrine
effects in oligo/amenorrhoea, hyperandrogenism and/or
PCOS for six herbal medicines. The quality of evidence, as
determined by the volume of pre-clinical studies and the
methodological quality of clinical trials, was highest for
the herbal medicines Vitex agnus-castus, Cimicifuga race-
mosa and Cinnamomum cassia, for which there were la-
boratory and/or animal studies demonstrating endocrine
mechanisms of action consistent with clinical outcomes
shown in RCT’s with low risks for bias. However, repli-
cated RCT data was only found for one herbal medicine,
Cimicifuga racemosa.
Evidence for Tribulus terrestris, Glycyrrhiza spp. alone
and in combination with Paeonia lactiflora and Paeonia
lactiflora with Cinnamomum cassia was limited by the
volume of laboratory and animal studies, with only one
to two studies found for each herb or herbal combin-
ation. There was supporting clinical data, however many
were small single arm, open label studies measuring
endocrine effects in healthy women. Evidence for these
herbal medicines is preliminary and in an emergent
phase.Discussion
This review synthesises the evidence for mechanisms of
effect for herbal medicine in oligo/amenorrhoea, hyperan-
drogenism and PCOS. Laboratory, animal and clinical
studies demonstrate that the herbal medicines Vitex
agnus-castus, Cimicifuga racemosa and Tribulus terrestris
initiate endocrine effects in the pituitary as measured by
lowered prolactin and LH and raised FSH. Four herbal
medicines, Tribulus terrestris, Glycyrrhiza spp., (alone and
in combination with Paeonia lactiflora), Paeonia lactiflora
(in combination with Cinnamomum cassia) and Cinna-
momum cassia demonstrated morphological changes in
polycystic ovaries and steroidogenesis, including reduced
ovarian volume and cysts, lowered androgens, improved
insulin sensitivity and increased oestradiol.
Clinical investigations found no adverse effects for the
six herbal medicines included in this review (Table 2).
A comparative study investigating the pharmaceutical
Bromocriptine and the herbal medicine Vitex agnus-
castus found no side effects associated Vitex agnus-castus
compared to 12.5% of participants taking Bromocriptine
reporting nausea and vomiting [63]. No studies comparing
the effectiveness for herbal medicines and the oral contra-
ceptive pill in PCOS, oligo/amenorrhoea and hyperandro-
genism were found.
Herbal medicine may present a treatment option for
women with oligo/amenorrhoea, hyperandrogenism and
PCOS as an adjunct or alternative treatment to pharma-
ceuticals with a high degree of acceptability by women
with PCOS [6]. Preliminary evidence for equivalent treat-
ment effects were found for the two pharmaceuticals and
three herbal medicines. These were bromocriptine, in the
management of hyperprolactinaemia andVitex agnus-
castus and clomiphene for infertility and ovulation induc-
tion and Cimicifuga racemosa and Tribulus terrestris.
Herbal medicine had positive adjunct effects with the
pharmaceuticals Spirinolactone in the management of
hyperandrogenism (Glycyrrhiza Spp.), and clomiphene for
PCOS related infertility (Cimicifuga racemosa). It is im-
portant however to highlight that evidence was provided
by a limited number of clinical studies, some with signifi-
cant risks for bias; particularly Tribulus terrestris, Glycyr-
rhiza glabra alone and in combination with Paeonia
lactiflora and Paeonia lactiflora in combination with
Cinnamomum cassia.
Selection of herbal medicines for the management of
PCOS often includes the combined prescription of Glycyr-
rhiza spp. and Paeonia lactiflora [72-75]. We found prelim-
inary evidence for this combination for hyperandrogenism
only, and the evidence was more robust for Glycyrrhiza
spp. alone than when combined with Paeonia lactiflora.
Comparatively, our findings for the combination of Peaonia
lactiflora and Cinnamomum cassia demonstrated no
change in androgen concentration, suggesting that the anti-
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flora combination more likely attributable to Glycyrrhiza
spp. However our findings may be complicated by the
aqueous extraction methods used in the Paeonia lacti-
flora and Cinnamomum cassia combination and the
preclinical studies into the Glycorrhizza spp and Paeo-
nia lactiflora combination. More research into the anti-
androgen effects of the combination Glycyrrhiza spp.
and Paeonia lactiflora is needed to clarify the anti-
androgen mechanism particularly if this herbal com-
bination remains cornerstone herbal management for
hyperandrogenism.
This review has some limitations. We used a meth-
odological approach which was deductive and not con-
sistent with traditional rationale for herbal selection.
Our inclusion criteria for clinical studies were specific
and relied upon our identification of herbal medicines
with preclinical (laboratory based) evidence explaining
the mechanisms of reproductive endocrinological ef-
fects in oligo/amenorrhoea, hyperandrogenism and
PCOS. Clinical studies were excluded from this review
due to the absence of evidence for whole herbal ex-
tracts. This was the case for Camellia sinensis (green
tea) for which only one laboratory study investigated
the effects of injecting epigallocatechin, a catechin
found in green tea in animals [76]. High quality clinical
evidence for Camellia sinensis was not presented in
this review due to the absence of pre-clinical data
explaining the mechanism for effect for the whole
herbal extract [77]. Mentha spicata (spearmint) was
another herbal medicine excluded from this review des-
pite the availability of high quality clinical evidence
demonstrating testosterone lowering effects in women
with PCOS [78]. We found no laboratory evidence de-
scribing the mechanism of action for Mentha spicata in
hyperandrogenism. Camilla sinensis and Mentha spi-
cata are examples of herbal medicines excluded from
this review due to not meeting the inclusion criteria.
Studies investigating western herbal medicines excluded
from this review are provided in Tables 3, 4 and 5.
Our search strategy may have restricted access due to
limited search terms. We didn’t include alternative spell-
ing of oestrogen and additional search terms for herbal
medicine could have been included to increase sensitivity
of the search.
This study synthesises the evidence for reproductive
endocrine effects for six whole herbal medicine extracts
that may be used to treat PCOS and associated oligo/
amenorrhoea and hyperandrogenism. The findings were
intended to add to clinicians understanding for the
mechanisms of action for herbal medicine for treatment
in these common conditions and reveal herbal medicines
with reproductive endocrinological effects, currently
demonstrated in scientific literature.Conclusions
Preclinical and clinical studies provide preliminary evi-
dence that six herbal medicines may have beneficial effects
for women with oligo/amenorrhea, hyperandrogenism
and PCOS. The quality of the evidence is variable and
strongest for Vitex agnus-castus and Cimicifuga racemosa
in the management of oligo/amenorrhea and infertility as-
sociated with PCOS; and Cinnamomum cassia for im-
proving metabolic hormones in PCOS. Evidence for
Tribulus terrestris, Glycyrrhiza spp. alone and in com-
bination with Paeonia lactiflora and Paeonia lactiflora
combined with Cinnamon cassia is promising but in
an emergent phase. Further investigations into the mecha-
nisms of effect for herbal extracts are needed to
complete our understanding of the reproductive endo-
crinological effects for herbal medicine for these common
conditions.
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